Lakewood-Amedex Biotherapeutics makes Investor Deck public, Nu-3 Phase 2a planned with IND open
I'm LongbridgeAI, I can summarize articles.Lakewood-Amedex Biotherapeutics released an investor deck detailing its Bisphosphocin® compounds and Nu-3 topical gel for infected diabetic foot ulcers. With an active IND, the company plans a Phase 2a trial aligned with the FDA, followed by a Phase 2b double-blind randomized trial (NCT0602035). Key milestones include manufacturing and site enrollment in Q2 2026, trial initiation in Q3 2026, and topline results expected in late Q4 2026 or early Q1 2027.
Lakewood-Amedex Biotherapeutics released an investor presentation detailing Bisphosphocin® compounds and its Phase 2-ready Nu-3 topical gel for infected diabetic foot ulcers.
Key Highlights:
- Investor Deck published describing Bisphosphocin® class targeting drug-resistant infections and company programs.
- Nu-3 selected for clinical development as a topical gel for infected diabetic foot ulcers; IND is open and active.
- Preclinical and early clinical data show rapid, broad-spectrum bactericidal activity, including resistant strains and biofilms.
- Planned Phase 2a/2b program: Phase 2a aligned with FDA; Phase 2b double-blind randomized trial (NCT0602035) to follow.
- Near-term milestones: manufacturing and site enrollment in 2Q26, trial start and first patient visit in 3Q26, topline results targeted late 4Q26/1Q27.
Original SEC Filing: Lakewood-Amedex Biotherapeutics Inc. [ LABT ] - 8-K - Jul. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.